Projects

ENDEVAOR (Environmental determinants of lifestyle behaviors and risk of type 2 diabetes and cardiovascular diseases)

This project further builds on the New Hoorn Study and the Diabetes Care System. Information on the built environment of participants will be added using geographic information systems (GIS), in order to comprehensively examine determinants of lifestyle behaviours and diabetes risk, depression and cardiovascular disease.

ARTEMIS: Vascular calcifications are associated with a 3- to 4-fold increased risk of cardiovascular diseases and are present in about 70% of diabetes patients. However, diabetes patients develop a specific form of vascular calcifications, not in the intima, but in the tunica media (medial calcifications). Studies suggest both forms of calcifications are distinct mechanisms leading to (different) cardiovascular outcomes. However, medial and intimal calcification are hardly distinguished in clinical research or practice. This study aims to investigate the risk factors and vascular consequences of intimal and medial calcifications in patients with type 2 diabetes in the Hoorn Diabetes Care System cohort. The study is funded by a senior postdoc stipendium from the Netherlands Heart Foundation and conducted in close collaboration with the Julius Center, University Medical Center Utrecht.

EARLY-HFPEF: Heart failure (HF) is a clinical syndrome with a worldwide increasing prevalence, a very high morbidity and mortality. Approximately 1–2 % of the adult population in developed countries has HF, with the prevalence rising to more than 10 % among persons 70 years of age or older. It is now well established that among HF patients, approximately half have preserved systolic function, also known as HF with preserved ejection fraction (HFPEF). HFpEF is highly prevalent in elderly women and frequently accompanied by co-morbidities such as obesity, metabolic syndrome, type 2 diabetes mellitus. Despite this, no strategies are available for early detection of HFPEF. The current collaboration aims to find diagnostic and prognostic clues to allow early detection of HFPEF. The project is funded by Cardiovasculair Onderzoek Nederland (CVON) and conducted in close collaboration with Prof. Paulus (VUmc, department of physiology) and Prof. Heymans (Maastricht University Medical Center).

RHAPSODY: RHAPSODY is a IMI funded consortium comprising 26 partners across Europe, including academic partners and industry. The project aims to identify new molecular biomarkers of pre-diabetes and T2D development and to define a molecular taxonomy of type 2 diabetes mellitus. Newly identified biomarkers will improve monitoring progression of the prediabetic state to T2D and allow improved patient stratification. To achieve this, it combines existing data from multiple large prospective (pre-) diabetic cohorts across Europe. Genetics, genomics, clinical, and biochemical data is stored in a  federated database that allows modeling of the data at a consortium-wide level.

PRIORITY: Priority is a FP7 funded project aiming to investigate that urinary proteomics can predict development of microalbuminuria (as a surrogate marker for the development of overt nephropathy) in type 2 diabetic patients with normal urinary albumin excretion. And, if early initiation of preventive therapy with spironolactonereduces risk of transition to microalbuminuria in those patients identified by urinary proteomics to be at high risk